We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | Successfully completed the 6 US FDA audit’s | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 | We are attending CPHI India from 29th Nov 2022 to 1st Dec 2022 |

About Srini


Srini Pharmaceuticals Private Limited is a global player in manufacturing and supply of Active Pharmaceutical Ingredients having USFDA, TGA and KFDA approvals. Multiproduct manufacturing facilities are located at Choutuppal near Hyderabad and Parawada, Jawaharlal Nehru Pharma City near Vishakapatanam .



Vision

We envision leveraging state of the art, ever evolving technologies, achieve realistic, attainable set targets within the specific timeline, delight customers, continue to maintain highest standards and become the most valued company for all stake holders.


Mission

To strive towards maintaining work ethics, responsible towards society, become environment friendly company, continuously study, analyze and research in the niche, reduce costs, risks, increase productivity, improve efficiency, invest in resources, and ensure continuous durable business growth, and enduring success.


Promoter

Dr. T.C. Reddy is the Managing Director of the Company. He is a Doctorate in Chemical Engineering with close to 3 decades of experience in different segments of the Pharma Industry ranging from the invention /improvement of molecules to marketing of the Bulk Drugs, Drug Intermediates and Formulations both in India and Abroad.

He worked extensively across multiple and leading fortune 500 companies in the U.S.A., putting to practice his technical skills and expertise, coupled with smart business acumen in manufacturing and marketing of API's and intermediates. This unique combination of technological expertise and sharp business skills has enabled him transform many organizations in the past and continuous to maintain the same level of efficiency, productivity and consistency at SRINI.